Tanin Intragumtornchai
Overview
Explore the profile of Tanin Intragumtornchai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Intragumtornchai T, Bunworasate U, Wudhikarn K, Lekhakula A, Julamanee J, Chansung K, et al.
Hematol Oncol
. 2017 Mar;
36(1):28-36.
PMID: 28332735
Systemic reports on the descriptive epidemiology of non-Hodgkin lymphoma (NHL) from Southeast Asia are scarce. A nationwide multi-institutional registry was conducted to compare the histopathology, clinical features, and survival of...
12.
Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Chuncharunee S, Niparuck P, et al.
Ann Hematol
. 2016 Oct;
96(1):57-64.
PMID: 27752821
Secondary central nervous system (CNS) relapse is a serious and fatal complication of diffuse large B cell lymphoma (DLBCL). Data on secondary CNS (SCNS) relapse were mostly obtained from western...
13.
Bachy E, Estell J, Van de Neste E, Bouabdallah R, Bargay J, Delmer A, et al.
Am J Hematol
. 2016 Jan;
91(4):410-5.
PMID: 26799234
An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved...
14.
Foss F, Advani R, Duvic M, Hymes K, Intragumtornchai T, Lekhakula A, et al.
Br J Haematol
. 2014 Nov;
168(6):811-9.
PMID: 25404094
Belinostat is a pan-histone deacetylase inhibitor with antitumour and anti-angiogenic properties. An open label, multicentre study was conducted in patients with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL)...
15.
Chanswangphuwana C, Kupatawintu P, Panjai P, Tunsittipun P, Intragumtornchai T, Bunworasate U
Int J Hematol
. 2014 Jan;
99(3):318-22.
PMID: 24474639
Pegfilgrastim is produced by binding a 20,000-dalton polyethylene glycol molecule to granulocyte colony-stimulating factor (G-CSF), increasing the mass of the compound, and resulting in a longer-lasting form of G-CSF. This...
16.
Kim S, Hsu C, Song Y, Tay K, Hong X, Cao J, et al.
Eur J Cancer
. 2013 Aug;
49(16):3486-96.
PMID: 23910494
Background: Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used for B-cell lymphoma. Thus, prevention and management of HBV reactivation are important in HBV-endemic areas. Methods:...
17.
Intragumtornchai T, Bunworasate U, Siritanaratkul N, Khuhapinant A, Nawarawong W, Norasetthada L, et al.
Leuk Lymphoma
. 2012 Jun;
54(1):83-9.
PMID: 22646050
The impact of health insurance with inequitable rituximab coverage on the survival of patients with diffuse large B-cell lymphoma (DLBCL) has never been reported. We conducted a nationwide multicenter analysis...
18.
Kim S, Moon J, Kim H, Kim J, Hwang Y, Intragumtornchai T, et al.
Leuk Lymphoma
. 2012 Jan;
53(8):1515-24.
PMID: 22273250
This retrospective study concerns non-bacterial infections in Asian patients receiving alemtuzumab. The clinical data of 182 patients treated with alemtuzumab alone or alemtuzumab-containing chemotherapy between the years 2003 and 2009...
19.
Watanaboonyongcharoen P, Na Nakorn T, Rojnuckarin P, Lawasut P, Intragumtornchai T
Int J Hematol
. 2012 Jan;
95(2):176-81.
PMID: 22234527
Individuals with monoclonal gammopathy of undetermined significance (MGUS) develop multiple myeloma and related malignancies at the rate of 1% per year. Given differences in ethnicity, data on prevalence and risk...
20.
Srimahachota S, Boonyaratavej S, Rerkpattanapipat P, Wangsupachart S, Tumkosit M, Bunworasate U, et al.
J Med Assoc Thai
. 2011 Jun;
94(6):657-63.
PMID: 21696072
Background: Stem cell transplantation is a potential treatment to improve left ventricular ejection fraction (LVEF) after ST elevation myocardial infarction (STEMI). However, the outcomes still are controversial. Objective: To determine...